Proof-of-concept studies demonstrated lonafarnib (LNF), a first-in-class oral prenylation inhibitor, efficacy in patients infected with HDV. The lonafarnib with ritonavir for HDV-2 (LOWR-2) study’s aim was to identify optimal combination regimens of LNF + ritonavir (RTV) ± pegylated interferon alpha (PEG-IFNα) with efficacy and tolerability for longer-term dosing. Here we report the safety and efficacy at end of treatment for up to 24 weeks.

中文翻译：

---

lonafarnib 和利托那韦联合或不联合干扰素 α 治疗慢性 δ 肝炎的 2 期剂量探索研究

概念验证研究表明，lonafarnib (LNF) 是一种一流的口服异戊二烯化抑制剂，对 HDV 感染的患者有效。lonafarnib 与利托那韦用于 HDV-2 (LOWR-2) 研究的目的是确定 LNF + 利托那韦 (RTV) ± 聚乙二醇干扰素 α (PEG-IFNα) 的最佳组合方案，具有长期给药的有效性和耐受性。在这里，我们报告了长达 24 周的治疗结束时的安全性和有效性。